Compare Ecopetrol SA (EC) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecopetrol SA vs Viatris Inc — how do they compare? Ecopetrol SA trades at $16.95 (market cap $33.69B), while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: Ecopetrol SA is the larger of the two by market cap, and Ecopetrol SA pays the higher dividend (3.82%). Which is the better fit depends on your goals.
| EC | VTRS | |
|---|---|---|
Market Cap | $33.69B | $18.69B |
Sector | Energy | Health |
52-Week High | $17.40 | $17.86 |
52-Week Low | $8.56 | $9.49 |
Enterprise Value | $63.86B | $30.80B |
Dividend Yield | 3.82% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ecopetrol (EC) trades at $16.945, down 0.62% today, with a bullish technical signal from moving averages but mixed earnings history including a Q2 2026 beat. The company maintains solid profitability with an 8.76% net margin and attractive valuation ratios like a P/E of 11.11. Recent news highlights a cybersecurity incident in July 2026 and ongoing acquisitions in Brazil, while cash flow improved in 2024 after a 2023 dip.
The stock presents a value opportunity with low multiples and strong cash generation, but faces headwinds from declining revenue trends, high debt levels, and operational risks. Analyst consensus is cautious with a $15.00 price target below current levels, suggesting limited near-term upside amid competitive and macroeconomic pressures in the energy sector.
Viatris (VTRS) trades at $16.105, down 1.07% on the day, with a bearish technical signal and mixed fundamentals. Recent Q2 2026 earnings beat estimates with EPS of $0.69 and revenue growth of 5%, but the company posted a net loss of $3.51B in 2025. Positive developments include FDA approval for Gwyn Lo and a raised 2026 outlook, though debt remains elevated at $14.04B long-term.
Outlook is cautious; while operational cash flow is strong at $2.32B and dividends provide income, persistent net losses and high P/E of 236.2 signal overvaluation risks. Analyst consensus leans Hold (61.54%), with upside potential if turnaround gains traction, but investors face headwinds from generic drug pricing pressures and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ecopetrol SA
Ecopetrol SA is a vertically integrated oil company with operations in Latin America and the United States Gulf Coast. Based out of Colombia, the company explores, develops, and conducts production activities in various countries. Ecopetrol works as the primary operator or partner in a joint venture, in a host of assets held onshore and offshore. Along with production, the company refines and markets crude oils and byproducts produced from its fields. Crude products are moved by Ecopetrol through a series of pipelines throughout Colombia, along with a network of third-party production centers and facilities.
Read more on EC →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
